← HeartSciences Inc. (HSCSW) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
HeartSciences Inc. (HSCSW)
Finance Services · market cap $240,009
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
20
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Doxycycline | Phase 2 | Emphysema |
| Mono-Therapy with Sildenafil | Phase 3 | Pediatric Pulmonary Hypertension |
| r-ATG | Phase 2 | Sickle Cell Disease |
| Metoprolol Succinate ER | Phase 2 | Healthy |
| Dilanubicel | Phase 2 | Acute Biphenotypic Leukemia |
| Convalescent Plasma | Phase 3 | Covid19 |
| Sodium Bicarbonate | Phase 2 | Chronic Kidney Disease |
| Nebulized Sodium Nitrite | Phase 2 | Heart Failure |
| Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric] | Phase 3 | Iron-deficiency |
| Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet | Phase 3 | Obesity |
| CTX-100 (formerly ETX-100) (hyaluronic acid) | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) |
| Peginterferon Alfa-2a and Ribavirin | Phase 2 | Hepatitis C |
| Mometasone | Phase 2 | Sickle Cell Disease |
| melatonin | Phase 2 | Traumatic Brain Injury |
| HBI-002 | Phase 2 | Anemia, Sickle Cell |
| Spironolactone 25mg | Phase 2 | Congenital Heart Disease |
| ALT-836 | Phase 2 | Sepsis |
| Haploidentical Bone Marrow Transplantation | Phase 2 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma |
| Fosinopril | Phase 3 | Microalbuminuria |
| Red blood cell units stored <= 10 days | Phase 3 | Cardiac Surgery |
Price & technical context
3-month
—
6-month
—
12-month
—
52-wk range
$0.04–$0.07
vs 50-day MA
—
vs 200-day MA
—
Realized vol
352.2%
Max drawdown
-42.9%
Daily closes through 2026-09-22. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HSCSW (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.